KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accounts Payables: 2009-2024

Historic Accounts Payables for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Accounts Payables fell 0.67% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 0.67%. This contributed to the annual value of $2.2 billion for FY2024, which is 15.33% down from last year.
  • Teva Pharmaceutical Industries' Accounts Payables amounted to $2.2 billion in FY2024, which was down 15.33% from $2.6 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Accounts Payables' 5-year high stood at $2.6 billion during FY2023, with a 5-year trough of $1.7 billion in FY2021.
  • Its 3-year average for Accounts Payables is $2.2 billion, with a median of $2.2 billion in 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' Accounts Payables skyrocketed by 37.89% in 2023 and then fell by 15.33% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Accounts Payables (MRY) stood at $1.8 billion in 2020, then decreased by 3.99% to $1.7 billion in 2021, then increased by 11.92% to $1.9 billion in 2022, then soared by 37.89% to $2.6 billion in 2023, then fell by 15.33% to $2.2 billion in 2024.
  • Its Accounts Payables stands at $2.2 billion for FY2024, versus $2.6 billion for FY2023 and $1.9 billion for FY2022.